Correction to: Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial (Hepatology, (2019), 70, (1690-1703), 10.1002/hep.30690);Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial

Hepatology

Volumn 70, Issue 5, 2019, Pages 1690-1703

  Bajaj, Jasmohan S ^a,b   Salzman, Nita H ^c   Acharya, Chathur ^a,b   Sterling, Richard K ^a,b   White, Melanie B ^a,b   Gavis, Edith A ^a,b   Fagan, Andrew ^a,b   Hayward, Michael ^c   Holtz, Mary L ^c   Matherly, Scott ^a,b   Lee, Hannah ^a,b   Osman, Majdi ^d   Siddiqui, Mohammad S ^d   Fuchs, Michael ^c   Puri, Puneet ^c   Sikaroodi, Masoumeh ^e   Gillevet, Patrick M ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Open Biome   (United States)

^e GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA DEFENSIN; ANTIBIOTIC AGENT; CADHERIN; DEFENSIN ALPHA 5; DEFENSIN ALPHA 6; INTERLEUKIN 6; LACTULOSE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAXIMIN; RNA 16S; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; BIFIDOBACTERIACEAE; BLOATING; BRAIN FUNCTION; CELLULITIS; CLINICAL ARTICLE; CLINICAL OUTCOME; COGNITION; COLON MUCOSA; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DUODENOSCOPY; ESOPHAGOGASTRODUODENOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FEVER; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFECTION; INTESTINE BIOPSY; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE INFECTION; LACHNOSPIRACEAE; LIVER CIRRHOSIS; MALE; MICROBIAL DIVERSITY; MICROCAPSULE; MODEL FOR END STAGE LIVER DISEASE SCORE; MRNA EXPRESSION LEVEL; NAUSEA AND VOMITING; PATIENT SAFETY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RUMINOCOCCACEAE; SIGMOIDOSCOPY; SINGLE BLIND PROCEDURE; STREPTOCOCCACEAE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; URINARY TRACT INFECTION; VEILLONELLACEAE; VIRGINIA; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PROCEDURES;

ADMINISTRATION, ORAL; CAPSULES; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 85067505516     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.31536     Document Type: Erratum

References (37)

1. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-735.
2. Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012;302:G168-G175.
3. Acharya C, Bajaj JS. Current management of hepatic encephalopathy. Am J Gastroenterol 2018;113:1600-1612.
4. Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol 2016;14:1181-1188.e2.
5. Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the Clinical Frailty Scale. Am J Gastroenterol 2016;111:1759-1767.
6. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332-2340.
7. Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016;64:200-208.
8. Lucidi C, Ginanni Corradini S, Abraldes JG, Merli M, Tandon P, Ferri F, et al. Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. Liver Transpl 2016;22:1333-1342.
9. Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017;66:1727-1738.
10. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015;149:223-237.
11. Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, et al. Diagnosis of minimal hepatic encephalopathy using stroop EncephalApp: a multicenter US-based, norm-based study. Am J Gastroenterol 2016;111:78-86.
12. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-773.
13. Liu TC, Gurram B, Baldridge MT, Head R, Lam V, Luo C, et al. Paneth cell defects in Crohn’s disease patients promote dysbiosis. JCI Insight 2016;1:e86907.
14. Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep 2015;5:18559.
15. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol 2011;12:R60.
16. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59-64.
17. Nardelli S, Allampati S, Riggio O, Mullen KD, Prakash R, Gioia S, et al. Hepatic encephalopathy is associated with persistent learning impairments despite adequate medical treatment: a multicenter, international study. Dig Dis Sci 2017;62:794-800.
18. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 2012;107:247-252.
19. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60:940-947.
20. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012;303:G675-G685.
21. Munoz L, Borrero MJ, Ubeda M, Conde E, Del Campo R, Rodriguez-Serrano M, et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis. Hepatology 2018 Nov 10. https://doi.org/10.1002/hep.30349. [Epub ahead of print]
22. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59-64.
23. Pijls KE, Jonkers DM, Elamin EE, Masclee AA, Koek GH. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int 2013;33:1457-1469.
24. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012;42:439-446.
25. Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis 2013;28:1-5.
26. Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013;8:e60042.
27. Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes after fecal microbiota transplant in cirrhosis. Gastroenterology 2019;156:1921-1923.e3.
28. Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol 2017;67:1084-1103.
29. Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol 2018;113:1177-1186.
30. Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014;307:G951-G957.
31. Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep 2016;6:34055.
32. Pustelny C, Komor U, Pawar V, Lorenz A, Bielecka A, Moter A, et al. Contribution of Veillonella parvula to Pseudomonas aeruginosa-mediated pathogenicity in a murine tumor model system. Infect Immun 2015;83:417-429.
33. Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017;23:8355-8366.
34. Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol 2013;108:1601-1611.
35. Riviere A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016;7:979.
36. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 2013;4:382-387.
37. Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol 2017;67:1084-1103.